Guidant
This article was originally published in The Gray Sheet
Executive Summary
European unit sales of coronary stents grew 19% in the third quarter, "driven by the launch of the Multi-Link Tetra," the company reports Oct. 12. The fourth-generation stent was approved for U.S. marketing on Oct. 3 (1"The Gray Sheet" Oct. 9, 2000, p. 16). Overall, stent revenues were $165 mil. worldwide and $111.5 mil. in the U.S. for the three months ended Sept. 30, reflecting declines of 20% and 24%, respectively. U.S. sales of implantable defibrillators, led by the Ventak Prizm, were up 24% to $137.6 mil., while domestic pacemaker sales, led by the Pulsar line, increased 11% to $88.1 mil. Guidant's third-quarter corporate revenue increased 6% to $600.8 mil., and net income advanced 25% to $122.8 mil